Teva Pharmaceutical Industries ADR(TEVA-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low32.70
Day High33.35
Open:33.02
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
GlobeNewswire
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Newswire.ca
Teva and Samsung Bioepis Enter Commercialization Agreement for OPUVIZ®, a Biosimilar Referencing Eylea® (aflibercept), in Canada
Tipranks
Scotiabank Keeps Their Buy Rating on Teva Pharmaceutical (TEVA)
Tipranks
Piper Sandler Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)
Tipranks
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA) and Irhythm Technologies (IRTC)
Tipranks
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)
GlobeNewswire
Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
Motley Fool
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Tipranks
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA) and Revolution Medicines (RVMD)
Motley Fool
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain?
GlobeNewswire
Teva Releases Q2 2026 Aide Memoire
GlobeNewswire
Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
GlobeNewswire
Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Ionis Pharmaceuticals (IONS) and Rhythm Pharmaceuticals (RYTM)
Motley Fool
Teva's Biosimilar Boom Is Just Getting Started. Is It Time to Buy This Rebounding Pharma Stock?
Tipranks
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Teva Pharmaceutical (TEVA) and Nuvation Bio (NUVB)
GlobeNewswire
Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy 

Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.